PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | The NEW ENGLAND JOURNAL Of MEDICINE

Authors: Andrea Cercek, M.D., Melissa Lumish, M.D. https://orcid.org/0000-0003-4173-5567, Jenna Sinopoli, N.P., Jill Weiss, B.A., Jinru Shia, M.D., MichelleLamendola-Essel, D.H.Sc., Imane H. El Dika, M.D., and Luis A. Diaz, Jr., M.D.

BACKGROUND

Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is caused by a deficiency in mismatch repair. Because mismatch repair–deficient colorectal cancer is responsive to programmed death 1 (PD-1) blockade in the context of metastatic disease, it was hypothesized that checkpoint blockade could be effective in patients with mismatch repair–deficient, locally advanced rectal cancer.

METHODS

We initiated a prospective phase 2 study in which single-agent dostarlimab, an anti–PD-1 monoclonal antibody, was administered every 3 weeks for 6 months in patients with mismatch repair–deficient stage II or III rectal adenocarcinoma. This treatment was to be followed by standard chemoradiotherapy and surgery. Patients who had a clinical complete response after completion of dostarlimab therapy would proceed without chemoradiotherapy and surgery. The primary end points are sustained clinical complete response 12 months after completion of dostarlimab therapy or pathological complete response after completion of dostarlimab therapy with or without chemoradiotherapy and overall response to neoadjuvant dostarlimab therapy with or without chemoradiotherapy.
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer

RESULTS

A total of 12 patients have completed treatment with dostarlimab and have undergone at least 6 months of follow-up. All 12 patients (100%; 95% confidence interval, 74 to 100) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging, 18F-fluorodeoxyglucose–positron-emission tomography, endoscopic evaluation, digital rectal examination, or biopsy. At the time of this report, no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months). No adverse events of grade 3 or higher have been reported.

CONCLUSIONS

Mismatch repair–deficient, locally advanced rectal cancer was highly sensitive to single-agent PD-1 blockade. Longer follow-up is needed to assess the duration of response. (Funded by the Simon and Eve Colin Foundation and others; ClinicalTrials.gov number, NCT04165772.)
Locally advanced rectal cancer is typically managed with multimodal therapy, including chemotherapy, radiation, and surgery. Current evidence supports a strategy involving the use of neoadjuvant therapy, in which induction chemotherapy with a fluoropyrimidine in combination with oxaliplatin is followed by chemoradiotherapy and then surgery.1-3 This approach results in a pathological complete response in up to a quarter of patients, but it is associated with marked complications and toxic effects — including bowel, urinary, and sexual dysfunction; infertility; and altered quality of life — in a substantial proportion of patients.4-6 In patients undergoing surgery, resection of the rectum is life-altering and often warrants a permanent diverting colostomy.6,7 Owing to the complications of surgery and the high frequency of pathological complete response, interest in organ-sparing nonoperative management is increasing. The use of clinical complete response that is achieved with neoadjuvant treatment as a surrogate for pathological complete response provides patients with a nonoperative option that results in a survival benefit that is similar to that in patients undergoing surgical resection.8-11
Approximately 5 to 10% of rectal adenocarcinomas are mismatch-repair deficient, and these tumors have been shown to respond poorly to standard chemotherapy regimens, including neoadjuvant chemotherapy in locally advanced rectal cancer.12-14 Immune checkpoint blockade alone has been shown to be highly effective as first-line treatment for patients with mismatch repair–deficient metastatic colorectal cancer, as well as for patients with treatment-refractory disease, with objective response rates of 33 to 55%, clinically significant durability of response, and prolonged overall survival.15-17
On the basis of the benefits seen in the context of metastatic disease, we hypothesized that single-agent programmed death 1 (PD-1) blockade alone might be beneficial in mismatch repair–deficient, locally advanced rectal cancer. To test this hypothesis, we initiated a phase 2 study to investigate the overall response and frequency of sustained clinical complete response to neoadjuvant treatment with dostarlimab, a PD-1 inhibitor, in this patient population.

Skip The Scoop | Seek Understanding

Montana Gov. Gianforte Signs Law Prohibiting Federal Ban on Gun Ownership

Show Me

Smithsonian museums, National Zoo announce reopening dates

Show Me

BREAKING EXCLUSIVE: FBI Finally Releases Records on Murdered DNC Analyst Seth Rich – Via Attorney Ty Clevenger

Show Me

Outrage after professor displays ‘juicy’ bones of black child killed in 1985 police bomb at lecture

Show Me

So Many Americans Look Around and Know | We Are Still At War With The Greatest Enemies of Freedom | Video: 2 Minutes 51 Seconds

Show Me

New York posts major increases in rape cases, sharply up from last year’s lockdown lows

Show Me

MLB Survey Asks Fans if They’re Republicans or Democrats

Show Me

Bannon’s War Room |Saturday Edition Hour 1 | Recorded April 24, 2021 | Video: 48 Minutes 45 Seconds

Show Me

Bannon’s War Room |Saturday Edition Hour 2 | Recorded April 24, 2021 | Video: 48 Minutes 45 Seconds

Show Me

Ghislaine Maxwell pleads NOT GUILTY to two more counts of sex trafficking

Show Me

(READ) Trump statement on Arizona election recount

Show Me

Feds Charge Southern Illinois U. Prof with Grant Fraud over Secret Ties to China

Show Me

Rumble CEO says alternative video platform has huge growth, as users ‘fed up’ with big tech

Show Me

‘What Are They Hiding?’: Democrats Try Last Attempt to Block AZ Election Audit & Cave In When Judge Asks For Million Dollar Bond

Show Me

US drop in vaccine demand has some places turning down doses

Show Me

Indian hospitals plead for oxygen as country sets daily coronavirus record

Show Me

Soros Makes First Contributions of 2022 Cycle

Show Me

What Happened to $16 Million Georgia’s Secretary of State’s Office Received Before the 2020 Election?

Show Me

SpaceX Rocketship Launches 4 Astronauts on NASA Mission to Space Station

Show Me

My, Oh, My. Some More Big Tech Pedophilia | “New Jersey man charged with sharing child porn through Facebook chat”

Show Me

Ron Johnson questions ‘big push’ to vaccinate ‘everybody’

Show Me

SURVEY: 85% Disbelieve Allegations Against Rep. Matt Gaetz.

Show Me

One Time FBI Informant, Al Sharpton, States: ‘We Are Seeing the Absolute Time that Policing Must Be Defined by the Federal Government’

Show Me

Norway’s Institute of Public Health Says, “Everyone in Norway will be at greater risk of disease and death by choosing the AstraZeneca vaccine than waiting for another”

Show Me

VIRGINIA: Attorney Who Helped Trump Fight 2020 Election In Court Announces Run For State Legislature

Show Me

Texas Sues Biden Administration for Allegedly Disregarding COVID-19 Rules at Border

Show Me

8-Year-Old Saves Sister Choking on Chicken Nugget Using Tip From John Cena

Show Me

Behind Bitcoin’s Recent Slide: Imploding Bets, Forced Liquidations

Show Me

Judicial Watch Fights Hard Left “Critical Race Theory”

Show Me

Joe Biden Masks Up for Zoom Call with 16 Other World Leaders. He’s the Only One.

Show Me

Russia: Activists detained under absurd “sanitary” charges for social media posts in support of public protest

Show Me

President Macron vows to ‘never give up the fight against Islamist terorrism’ after knifeman screaming ‘Allahu Akbar’ stabs woman to death before being shot dead by cops at French police station

Show Me

‘I Am Nonviolent’: Maxine Waters Defends Call For Protesters To ‘Get More Confrontational’

Show Me

African Activists: The Earth Is in Peril If Wealthy Nations Don’t Slash Emissions & Pay Climate Debt

Show Me

Caitlyn Jenner files to run for governor, done with one-party rule: This is not Gavin Newsom’s California

Show Me

April 23, 2021 | Nightly News Rebroadcast | Video: 51 Minutes 28 Seconds

Show Me

Bannon’s War Room | Morning Edition Hour 1 | Recorded April 23, 2021 | Video: 48 Minutes 58 Seconds

Show Me

Bannon’s War Room | Morning Edition Hour 2 | Recorded April 23, 2021 | Video: 48 Minutes 54 Seconds

Show Me

Bannon’s War Room | Evening Edition | Recorded April 23, 2021 | Video: 48 Minutes 30 Seconds

Show Me

Bannon’s War Room |Evening Edition Hour 2 | Recorded April 23, 2021 | Video: 48 Minutes 58 Seconds

Show Me